Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Letter From The Editor

I was at a program last week and we were talking about testosterone replacement in men and how our patients often go for years with low levels. There was a lot of conversation about testing and why it does not get done and one of the prescribers in attendance shared her secret for deciding if a man needed to have a testosterone level drawn.

She described it as "boney bottom syndrome" and let us know she asks her older patients if their bottoms hurt if they sit on a hard chair for more than 20 minutes. If they answer yes then she orders the test. Accordingly, most of the time if the bottom hurts then the testosterone is low. This week's Item #7, Testosterone Treatment Helps Older Males Lose Weight, Plus Other Benefits, lends credence to her idea and takes it a step further by adding a few more benefits.

There is even more reason to focus on any therapy that will help with weight loss as Item #11, Obesity Projected to Grow to 42% in U.S., points to the tremendous increase in obese patients we will be seeing in the next 18 years.

If you are attending the AACE Conference in Philadelphia next week be sure and stop by our booth to enter our contest for a free Kindle Fire. 

*****

Announcements:

dLife.com: May 13, 7PM ET on CNBC

Topics: dLife’s Benno Schmidt reports on the controversial topic of medical alert tattoos, and gets inked himself. Plus, a look at how diabetes may impact memory, and how to keep yours sharp; and a low carb chocolate treat from the dLife kitchen. Sundays on CNBC at 7 PM ET, 6 PM CT, and 4 PM PT. Catch up on dLife.com

TCOYD Conference and Health Fair, Raleigh Convention Center, Raleigh, North Carolina, Saturday, May 19, 2012

Join Steven Edelman, MD and Featured Speaker, Ben Vereen, (Singer, Dancer, Actor) for a day focused on diabetes education, health and wellness.

Please answer this week's poll: Generics are usually just as safe and effective as the corresponding name-brand product....

Vote in and then see results from previous polls here.

*****************************
We can make a difference!
*****************************

Check out this week's "Test Your Diabetes Knowledge" question!

Dave Joffe, Editor-in-chief 

 … Read More

Scroll down for items in the current newsletter

Newsflash

FDA Panel Gives Nod to New Diet Drug

An FDA advisory committee has voted 18-4, with one abstention, in favor of approving lorcaserin hydrochloride (Lorqess). It would be the first new weight loss drug in more than a decade. 

 




Tool for your Practice

Chart of Pharmacokinetics of Current Insulin Preparations


Pharmacokinetics_Insulin_PrepThis is a current chart of insulins, with type, product name, onset, peak and duration. Just follow this link to download the Chart of Pharmacokinetics of Current Insulin Preparations (pdf).

 




Product of the Week

Korlym

Korlym

Mifepristone (Korlym™, Corcept Therapeutics Inc.), was approved to manage hyperglycemia in patients with endogenous Cushing's syndrome and type 2 diabetes mellitus or glucose intolerance who are not candidates for surgery or in whom surgical treatment has failed. This cortisol receptor blocker has potent antiprogestational properties and should never be used in pregnant women due to risk for pregnancy termination. Pregnancy must be excluded in women of reproductive age prior to initiation of therapy or if treatment is interrupted for more than 14 days.

 

Diabetes In Control Has Over 11000 Studies & Articles In Our Archives

Quote of the Week!

"Success usually comes to those who are too busy to be looking for it."

       ...............Henry David Thoreau

 
Diabetes In Control Advertisers
 
 
Cast Your Vote
Generics are usually just as safe and effective as the corresponding name-brand product.

Navigate Diabetes In Control
CME/CE of the Week
John Steinberg, DPM

Category: Diabetic Foot
Credits:
 .75


Advertisement


Search Articles On Diabetes In Control